Several studies have assessed PC incidence within families with BRCA2 pathogenic variants demonstrating a 4.4–5.9 relative risk (lifetime risk 5–8%), with a slightly higher risk for males [30–32]. The gene discussed is BRCA2; the disease is pachyonychia congenita.